Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 785-792

  Taurin, Sebastien ^a   Allen, Kirstie M ^a   Scandlyn, Marissa J ^a   Rosengren, Rhonda J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Breast cancer; Epidermal growth factor receptor; Estrogen receptor negative; Raloxifene; Selective estrogen receptor modulator

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM INVASIVENESS; RALOXIFENE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84880609587     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2012     Document Type: Article

References (47)

1. Sporn MB, Dowsett SA, Mershon J and Bryant HU: Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther 26: 830-840, 2004.
2. Jordan VC and Koerner S: Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. J Endocrinol 64: 193-194, 1975.
3. Croxtall JD, Emmas C, White JO, Choudhary Q and Flower RJ: Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharmacol 47: 197-202, 1994.
4. Couldwell WT, Weiss MH, DeGiorgio CM, et al: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993.
5. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403-1405, 1984.
6. Murphy LC and Sutherland RL: Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro. Endocrinology 116: 1071-1078, 1985.
7. Plowman PN: Tamoxifen as adjuvant therapy in breast cancer. Current status. Drugs 46: 819-833, 1993.
8. Mandlekar S and Kong ANT: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477, 2001.
9. Carey LA, Dees EC, Sawyer L, et al: The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.
10. Kaplan HG and Malmgren JA: Impact of triple-negative phenotype on breast cancer prognosis. Breast J 14: 456-463, 2008.
11. Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs 29: 87-97, 2011.
12. Taurin S, Sandbo N, Qin Y, Browning D and Dulin NO: Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281: 9971-9976, 2006.
13. Reagan-Shaw S, Nihal M and Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
14. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
15. Rush JS, Quinalty LM, Engelman L, Sherry DM and Ceresa BP: Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem 287: 712-722, 2012.
16. Ueno NT and Zhang D: Targeting EGFR in triple-negative breast cancer. J Cancer 2: 324-328, 2011.
17. Nickerson NK, Mohammad KS, Gilmore JL, et al: Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One 7: e30255, 2012.
18. Zoncu R, Perera RM, Balkin DM, Pirruccello M, Toomre D and De Camilli P: A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell 136: 1110-1121, 2009.
19. Pol A, Lu A, Pons M, Peiró S and Enrich C: Epidermal growth factor-mediated caveolin recruitment to early endosomes and MAPK activation. J Biol Chem 275: 30566-30572, 2000.
20. Freedman VH and Shin SI: Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3: 355-359, 1974.
21. Riggs BL and Hartmann LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348: 618-629, 2003.
22. Perry RR, Kang Y and Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2: 238-245, 1995.
23. Gelmann EP: Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst 88: 224-226, 1996.
24. Kim HT, Kim BC, Kim IY, et al: Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem 277: 32510-32515, 2002.
25. Eisen SF and Brown HA: Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells. Mol Pharmacol 62: 911-920, 2002.
26. Todorova VK, Kaufmann Y, Luo S and Klimberg VS: Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 67: 285-291, 2011.
27. Bosch A, Eroles P, Zaragoza R, Vina JR and Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36: 206-215, 2010.
28. Cho EY, Chang MH, Choi YL, et al: Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol 68: 753-761, 2011.
29. Hyatt DC and Ceresa BP: Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Exp Cell Res 314: 3415-3425, 2008.
30. de Medina P, Payre B, Boubekeur N, et al: Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ 16: 1372-1384, 2009.
31. de Medina P, Paillasse MR, Segala G, Poirot M and Silvente-Poirot S: Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc Natl Acad Sci USA 107: 13520-13525, 2010.
32. Payre B, de Medina P, Boubekeur N, et al: Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther 7: 3707-3718, 2008.
33. Simonsen A and Tooze SA: Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. J Cell Biol 186: 773-782, 2009.
34. Razi M, Chan EY and Tooze SA: Early endosomes and endosomal coatomer are required for autophagy. J Cell Biol 185: 305-321, 2009.
35. Sigismund S, Woelk T, Puri C, et al: Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102: 2760-2765, 2005.
36. Aguilar RC and Wendland B: Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci USA 102: 2679-2680, 2005.
37. Couet J, Sargiacomo M and Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997.
38. Litwiniuk MM, Roznowski K, Filas V, et al: Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer 8: 100, 2008.
39. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J and Lupu R: Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep 7: 157-167, 2000.
40. Kuiper GGJM, Lemmen JG, Carlsson B, et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139: 4252-4263, 1998.
41. Pinton G, Thomas W, Bellini P, et al: Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One 5: e14110, 2010.
42. Lee W-L, Chao H-T, Cheng M-H and Wang P-H: Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 60: 92-107, 2008.
43. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006.
44. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z and Wang ZY: A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780, 2011.
45. Lin SL, Yan LY, Zhang XT, et al: ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013, 2010.
46. Nguyen DX, Bos PD and Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
47. Viale G, Rotmensz N, Maisonneuve P, et al: Invasive ductal carcinoma of the breast with the 'triple-negative' phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116: 317-328, 2009.